Imugene Ltd (IMU):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Imugene Ltd (IMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11518)・商品コード:DATA904C11518
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene’s lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd (IMU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Imugene Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11
Imugene Enters Into Partnership with Medical University of Vienna 12
Imugene Enters into Agreement with Novotech 13
Licensing Agreements 14
Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14
Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15
Equity Offering 16
Imugene to Raise USD6.2 Million in Rights Offering of Shares 16
Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17
Imugene Raises USD1.6 Million in Rights Offering of Shares 18
Imugene Completes First Tranche Of Private Placement Of Shares For US$0.76 Million 19
Imugene Completes Rights Offering Of Shares For US$0.19 Million 20
Acquisition 21
Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21
Imugene Ltd – Key Competitors 22
Imugene Ltd – Key Employees 23
Imugene Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board 25
Sep 18, 2018: Imugene names Tanios Bekaii – Saab to Scientific Advisory Board 26
Aug 23, 2018: Imugene names Dr Mark Marino Chief Medical Officer 27
Mar 28, 2018: Leslie Chong Appointed as Managing Director 28
Product News 29
Jul 23, 2018: Imugene: PD-1 cancer vaccine development update 29
02/12/2018: Novel Anti-PD-1 Mimotope Vaccine Ready for Development 30
Clinical Trials 31
Feb 13, 2017: Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research 31
Other Significant Developments 33
Oct 30, 2018: Imugene: Business update – Appendix 4C for the quarter ended 33
Jul 31, 2018: Imugene: Business Update – Appendix 4C for the quarter ended 30 June 2018 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Imugene Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Imugene Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11
Imugene Enters Into Partnership with Medical University of Vienna 12
Imugene Enters into Agreement with Novotech 13
Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14
Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15
Imugene to Raise USD6.2 Million in Rights Offering of Shares 16
Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17
Imugene Raises USD1.6 Million in Rights Offering of Shares 18
Imugene Completes First Tranche Of Private Placement Of Shares For US$0.76 Million 19
Imugene Completes Rights Offering Of Shares For US$0.19 Million 20
Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21
Imugene Ltd, Key Competitors 22
Imugene Ltd, Key Employees 23
Imugene Ltd, Subsidiaries 24

List of Figures
Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Imugene Ltd (IMU):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11518)販売に関する免責事項を必ずご確認ください。
★調査レポート[Imugene Ltd (IMU):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆